Angel money rotates: life sciences absorbed nearly half the dollars

The ACA published the report on 13 July 2026, drawing on data contributed by member groups in the US and Canada. The headline is benign: reported angel investment rose 12% year over year, from $437 million in 2024 to $491.3 million in 2025. The interesting part is not the total but the allocation. The ACA records groups deploying more capital per investment and per company — greater selectivity — and describes 2025 as the first sign of a disciplined recovery after several years of post-pandemic correction.

Why the life-sciences share moved so fast

On the report's data, the life-sciences share of angel dollars moved from 31% in 2023 to 37% in 2024 and to nearly 47% in 2025. Three years, almost half the money. The mechanism is not mysterious: rounds in the sector tend to be larger, tied to explicit technical or regulatory milestones, and funded in tranches. When angel groups shift to bigger cheques into fewer companies, life-sciences capital structures benefit first. In parallel, roughly two-thirds of reporting groups made at least one AI investment — AI takes deal count, life sciences takes dollars.

The wider backdrop points the same way. Crunchbase data shows global startup investment hit a record $510 billion in the first half of 2026, above the $440 billion invested in all of 2025 — while Crunchbase also notes the increase comes from larger cheques, not more of them. Angels are playing on the same table: more money for consensus themes, fewer doors for everything else.

Rotating sector means rewriting the portfolio maths

An angel portfolio tilted to life sciences differs not only in content but in time and reserves. Capital waits for preclinical data, device filings, distribution partners — while software can answer its market question in a few quarters. The ACA points to a building pipeline of potential exits, but a pipeline is not cash in hand. For individual investors the practical consequences are three: keep a follow-on reserve, accept longer holding periods, and buy diligence capability by co-investing with domain specialists.

• How much capital is needed to reach the next milestone, and who validates it: a regulator, a hospital, or the company itself?
• Who leads the next round, and have they funded this class of regulatory filing before?
• If the next round slips six months, what keeps the company alive: service contracts, research grants, or only new equity?
• Who are the plausible acquirers, and at what stage do they buy — after trials, or after revenue?
• Does our angel group have anyone who can read this sector's data, or are we leaning on a lead investor's reputation?

The other side of the number matters. The 12% increase is capital deployed, not returns realised. A portfolio concentrated in a long-duration sector looks good on valuation marks long before it looks good on cash flow. This is market reporting, not investment advice: what the ACA data states clearly is that allocation behaviour has changed; the outcome depends on the M&A cycle.